| Literature DB >> 34886185 |
Lisa Riemann1, Johanna Sophie Lubasch1, Axel Heep2, Lena Ansmann1.
Abstract
About 8% of all children and adolescents worldwide are affected by chronic diseases. Managing chronic conditions requires pediatric patients to be health literate. The purpose of this review is to examine the existing evidence on the links between health literacy and its outcomes proposed by the model by Sørensen et al. in chronically ill pediatric patients. Four electronic databases (PubMed, Scopus, CINAHL, PsycINFO) were searched to identify pertinent articles published up to November 2021. The search was conducted independently by two researchers and restricted to observational studies. Of 11,137 initial results, 11 articles met eligibility criteria. Overall, 6 studies identified a significant association between health literacy and one of the considered outcomes. Regarding health behavior, none of the studies on adherence found significant associations with health literacy. The results in terms of health service use were inconclusive. Regarding health outcomes, health literacy did not affect most physiological parameters, but it significantly improved health-related quality of life. Overall, evidence remains inconclusive but suggests that health literacy is associated with self-efficacy, health-related quality of life, and health service use in pediatric patients. Further research should be undertaken to strengthen the evidence.Entities:
Keywords: adolescents; children; chronic conditions; empowerment; health behavior; health literacy; health outcomes; review
Mesh:
Year: 2021 PMID: 34886185 PMCID: PMC8656602 DOI: 10.3390/ijerph182312464
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Eligibility criteria.
| Criterion | Inclusion | Exclusion |
|---|---|---|
| Population |
Sample or subsample composed of children and adolescents under the age of 18 years diagnosed with a chronic disease Samples that included the defined age group but additionally included patients up to 30 years of age without differentiating their analysis by age groups were included as well |
Sample composed of persons aged 18 years and older only Healthy children and adolescents Acute diseases |
| Focus/outcomes |
Impact of health literacy in children and adolescents affected by chronic diseases on outcome categories defined by Sørensen et al. (health behavior, health outcomes, health service use, empowerment, participation, health costs, equity, and sustainability) |
Health literacy of parents or caregivers Health literacy in children without chronic diseases |
| Study design |
Observational studies |
Interventional studies Meta-analyses Systematic reviews Randomized controlled trials Qualitative studies Case reports Expert opinions |
| Language |
English, German |
Studies in any language other than English or German |
Figure 1Screening process.
Study characteristics.
| Author | Publication Year | Country | Study Design | Sample Size | Median Age of Participants (Range) | Health Issues |
|---|---|---|---|---|---|---|
|
| 2019 | Netherlands | Prospective cohort study | 390 | 15 (12–18) | Psychosocial/mental diseases |
|
| 2019 | USA | Cross-sectional study | Total: 79 | Total: N/A (N/A) | Liver transplant recipients |
|
| 2019 | Ireland | Retrospective cohort study | 251 | 21.38 (13–30) | Cystic fibrosis |
|
| 2018 | USA | Retrospective cohort study | 49 | N/A (12–18) | Chronic kidney diseases, |
|
| 2019 | USA | Cross-sectional study | 65 | 15.03 (13–17) | Diabetes mellitus type 1 |
|
| 2010 | USA | Longitudinal cohort study | 186 | 20.5 (16–24) | HIV |
|
| 2014 | USA | Cross-sectional study | 50 | 19.7 (13–24) | HIV |
|
| 2011 | USA | Cross-sectional study | 78 | 11.5 (10–16) | Obesity |
|
| 2016 | USA | Cross-sectional study | 181 | N/A (15–19) | Asthma |
|
| 2018 | USA | Cross-sectional study | 327 | 15.8 (13–18) | Asthma |
|
| 2020 | USA | Cross-sectional study | Total: 59 | Total: N/A (12–29) | Chronic kidney disease, hypertension |
USA, United States of America; N/A, not available; SLE, systematic lupus erythematosus; HIV, human immunodeficiency virus.
Quality assessment.
| Criterion | Beukema et al. (2019) | Dore-Stites et al. (2019) | Jackson et al. (2019) | Levine et al. (2018) | Manegold et al. (2019) | Murphy et al. (2010) | Navarra et al. (2014) | Sharif et al. (2011) | Valerio et al. (2016) | Valerio et al. (2018) | Zhong et al. (2020) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 17 | 9.5 | 11.5 | 9.5 | 9 | 12 | 12 | 12.5 | 11 | 8.5 | 12.5 |
Quality assessment.
| Criterion | Beukema et al. (2019) | Dore-Stites et al. (2019) | Jackson et al. (2019) | Levine et al. (2018) | Manegold et al. (2019) | Murphy et al. (2010) | Navarra et al. (2014) | Sharif et al. (2011) | Valerio et al. (2016) | Valerio et al. (2018) | Zhong et al. (2020) |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| 1: Hypothesis/aim/objective clearly described | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 |
| 2: Main outcomes in introduction or methods | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 |
| 3: Patient characteristics clearly described | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4: Interventions of interest clearly described | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5: Principal confounders clearly described | 2 | 0 | 0 | 2 | 0 | 1 | 2 | 2 | 0 | 0 | 2 |
| 6: Main findings clearly described | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 |
| 7: Estimates of random variability provided for main outcomes | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 |
| 8: All adverse events of intervention reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9: Characteristics of patients lost to follow-up described | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 10: Probability values reported for main outcomes | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|
| |||||||||||
| 11: Subjects asked to participate were representative of source population | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 0 |
| 12: Subjects prepared to participate were representative of source population | 1 | 0.5 | 0.5 | 0 | 0 | 0.5 | 0 | 0.5 | 1 | 0 | 0.5 |
| 13: Location and delivery of study treatment was representative of source population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| |||||||||||
| 14: Study participants blinded to treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 15: Blinded outcome assessment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 16: Any data dredging clearly described | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 17: Analyses adjust for differing lengths of follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18: Appropriate statistical tests performed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 19: Compliance with interventions was reliable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 20: Outcome measures were reliable and valid | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 21: All participants recruited from the same source population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 22: All participants recruited over the same period | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 23: Participants randomized to treatment(s) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 24: Allocation of treatment concealed from investigators and participants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 25: Adequate adjustment for confounding | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| 26: Losses to follow-up taken into account | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| |||||||||||
| 27: Sufficient power to detect treatment effect at significance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Influence of health literacy on health outcomes.
| Outcome | Regarded in | Study | Negative Correlation | Positive Correlation ( |
|---|---|---|---|---|
|
|
| |||
| Adherence | 4 | Beukema et al. | No | Yes (0.23) |
| Dore-Stites et al. | N/A | N/A | ||
| Murphy et al. | No | Yes (0.98) | ||
| Navarra et al. TOFHLA REALM-Teen | ||||
| Self-management/care | 3 | Beukema et al. | No | Yes (0.16) |
| Valerio et al., 2016 Rescue medication Controller medication | ||||
| Zhong et al. | No |
| ||
|
|
| |||
| Emergency department (ED) visits/hospitalization/hospital stays | 4 | Jackson et al. Outpatient visits Days hospitalized | ||
| Levine et al. | N/A | N/A | ||
| Murphy et al. ED visits: ≥1 (ref. none) Overnight hospital stays: ≥1 (ref. none) | ||||
| Valerio et al., 2016 | No |
| ||
| Medical care received | 1 | Murphy et al. | No |
|
|
|
| |||
| Physiological parameters/clinical characteristics | 5 | Dore-Stites et al. | N/A | N/A |
| Jackson et al. ppFEV1 BMI Pseudomonas aeruginosa Number of iv antibiotics Duration of iv antibiotics Number of oral antibiotics Duration of oral antibiotics | ||||
| Manegold et al. Glycemic control | ||||
| Murphy et al. CD4 cells Viral load | ||||
| Sharif et al. | No |
| ||
| Morbidity | 3 | Beukema et al. | No |
|
| Valerio et al., 2016 | No | Yes (0.404) | ||
| Valerio et al., 2018 Symptom bother Symptom days | ||||
| HRQoL | 2 | Jackson et al. | No |
|
| Valerio et al., 2016 | No |
| ||
|
|
| |||
| Self-efficacy | 3 | Murphy et al. Adherence to medication regimes Keeping of medical appointments | ||
| Sharif et al. | No |
| ||
| Valerio et al., 2018 | No |
| ||
| Transition readiness | 2 | Manegold et al. | No | Yes (0.50) |
| Zhong et al. | No |
|
N/A, not available; HL, health literacy; ED, emergency department; ppFEV1, percent predicted forced expiratory pressure in 1 s; BMI, body mass index; iv, intravenous; HRQoL, Health-Related Quality of Life; bold text indicates statistically significant results.
Study characteristics.
| Author | Publication Year | Country | Study Design | Sample Size | Median Age of Participants (Range) | Health Issues | Health Literature Measure | Outcomes |
|---|---|---|---|---|---|---|---|---|
|
| 2019 | Netherlands | Prospective cohort study | 390 | 15 (12–18) | Psychosocial/mental diseases | 3-item HL Screening questions | Adherence |
|
| 2019 | USA | Cross-sectional study | Total: 79 | Total: N/A (N/A) | Liver transplant recipients | TOFHLA | Adherence (tacrolimus blood level) |
|
| 2019 | Ireland | Retrospective cohort study | 251 | 21.38 (13–30) | Cystic fibrosis | HLS-EU-Q16 | HRQoL (CFQr) |
|
| 2018 | USA | Retrospective cohort study | 49 | N/A (12–18) | Chronic kidney diseases, SLE, kidney transplant, dialysis | Newest vital sign | ED visits |
|
| 2019 | USA | Cross-sectional study | 65 | 15.03 (13–17) | Diabetes mellitus type 1 | TOFHLA-R | Transition readiness (TRAQ) |
|
| 2010 | USA | Longitudinal cohort study | 186 | 20.5 (16–24) | HIV | TOFHLA | Viral load, CD4 cells |
|
| 2014 | USA | Cross-sectional study | 50 | 19.7 (13–24) | HIV | TOFHLA | Adherence to ART (BAMS) |
|
| 2011 | USA | Cross-sectional study | 78 | 11.5 (10–16) | Obesity | STOFHLA | BMI |
|
| 2016 | USA | Cross-sectional study | 181 | N/A (15–19) | Asthma | 3-item HL screening questions | HLQoL (MiniPAQLQ) |
|
| 2018 | USA | Cross-sectional study | 327 | 15.8 (13–18) | Asthma | REALM-Teen | Asthma self efficacy |
|
| 2020 | USA | Cross-sectional study | Total: 59 | Total: N/A (12–29) | Chronic kidney disease, hypertension | Newest vital sign | HCT readiness (STARx Questionnaire) |
N/A, not available; HL, Health Literaca; ART, Anti-Retroviral Therapy; HCT, Health Care Transition; ED, Emergency Department; SDQ, Dutch self-reported and parent-reported versions of Strengths and Difficulties Questionnaire; TOFHLA, Test of Functional Health Literacy in Adults; REALM-Teen, Rapid Estimate of Adult Literacy in Medicine; BAMS, Beliefs About Medication Scale; ESES, Eating Self-Efficacy Scale; MiniPAQLQ, Mini Pediatric Asthma Quality of Life Questionnaire; STARx, Self-Management and Transition to Adulthood with Rx treatment questionnaire.
Influence of health literacy on outcomes.
| Outcome | Regarded in | Positive Correlation | Reported Estimate | 95% CI |
|
|---|---|---|---|---|---|
|
|
| ||||
| Adherence | 4 | Beukema et al. | 0.43 (β coefficient) | −0.27, 1.14 | 0.23 |
| Dore-Stites et al. | N/A | N/A | N/A | ||
| Murphy et al. ≥90% adherence (ref. 0%) >0% and <90% (ref. 0%) | |||||
| Navarra et al. TOFHLA REALM-Teen | |||||
| Self-management/care | 3 | Beukema et al. Improved understanding | |||
| Valerio et al., 2016 Rescue medication Controller medication | |||||
| Zhong et al. Adequate HL (ref. Low/moderate HL) |
| ||||
|
|
| ||||
| ED visits/hospitalization/hospital stays | 4 | Jackson et al. Outpatient visits Days hospitalized | |||
| Levine et al. ED visits Preventable hospitalizations Total hospitalizations Total number of days inpatient | |||||
| Murphy et al. ED visits: ≥1 (ref. none) Overnight hospital stays: ≥1 (ref. none) | |||||
| Valerio et al., 2016 Hospitalization and inadequate HL |
| ||||
| Medical care received | 1 | Murphy et al. Medical care received ≥3 times (ref. 0) 1–2 times (ref. 0) |
| ||
|
|
| ||||
| Physiological parameters/clinical characteristics | 5 | Dore-Stites et al. AST, ALT, TBili | |||
| Jackson et al. ppFEV1 Body mass index Pseudomonas aeruginosa Number of iv antibiotics Duration of iv antibiotics Number of oral antibiotics Duration of oral antibiotics | |||||
| Manegold et al. Glycemic control | |||||
| Murphy et al. CD4 cells Viral load | |||||
| Sharif et al. Body mass index |
| ||||
| Morbidity | 3 | Beukema et al. Psychosocial problems |
| ||
| Valerio et al., 2016 Moderate–severe asthma | |||||
| Valerio et al., 2018 Symptom bother Symptom days | |||||
| HRQoL | 2 | Jackson et al. | 0.23 (correlation coefficient) | 0.11–0.35 |
|
| Valerio et al., 2016 | 0.75 (odds ratio) | 0.59, 0.95 |
| ||
|
|
| ||||
| Self-efficacy | 3 | Murphy et al. To adhere to medication regimens: mean ≥4 (ref. mean <4) To keep medical appointments: mean ≥4 (ref. mean <4) | |||
| Sharif et al. | −0.45 | N/A |
| ||
| Valerio et al., 2018 | 1.28 (β coefficient) | 0.23, 2.32 |
| ||
| Transition readiness | 2 | Manegold et al. | −0.10 (correlation coefficient) | 0.50 | |
| Zhong et al. Adequate HL (ref. Low/moderate HL) |
|
N/A, not available; HL, health literacy; ED, emergency department; ppFEV1, percent predicted forced expiratory pressure in 1 s; iv, intravenous; bold text indicates statistically significant results.